Saturday, September 10, 2022 4:09:59 AM
I think there is something not many factored in. The trial started enrolling sicker patients halfway through enrollment.
1/2 of 116 is 58. 58 -17 = 41. For simplicity sake let’s say
58% of control were healthier when randomized on average.
41% of control were sicker when randomized on average.
That means there was a difference of 17% more healthy.
In the treatment group
50% healthier on average
50% sicker on average
Maybe we need to wait and see what the data really shows us. If, we assume that 34 sicker patients on average entered the treatment group after the control decided not to enroll its final 17, then you might see more clearly what the parties were dealing with.
Anyway, I’m not certain, you, Ex, myself or anyone else understands what the researchers and regulators were trying to tease out. We just have to wait.
Perhaps the treatment group did better then many think when one takes into consideration they faced more adversity.
1/2 of 116 is 58. 58 -17 = 41. For simplicity sake let’s say
58% of control were healthier when randomized on average.
41% of control were sicker when randomized on average.
That means there was a difference of 17% more healthy.
In the treatment group
50% healthier on average
50% sicker on average
Maybe we need to wait and see what the data really shows us. If, we assume that 34 sicker patients on average entered the treatment group after the control decided not to enroll its final 17, then you might see more clearly what the parties were dealing with.
Anyway, I’m not certain, you, Ex, myself or anyone else understands what the researchers and regulators were trying to tease out. We just have to wait.
Perhaps the treatment group did better then many think when one takes into consideration they faced more adversity.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
